Other targetable sarcomas.
Despite complex genetics, aneuploid tumors like dedifferentiated liposarcoma have specific and reproducible chromosomal changes such as amplification of HDM2 and CDK4 that represent potential targets for systemic therapy. In addition, there are cancer cell survival pathways that may not be the target of chromosomal translocations or mutations that are still estimable targets for new systemic therapeutics, be it pathways involved in angiogenesis or apoptosis. In this review, we examine target selection for specific sarcoma subtypes, and demonstrate with a few examples new techniques being used to delineate novel therapeutic inroads for patients with sarcoma.
Pires de Camargo
Veridiana
V
Sarcoma Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
van de Rijn
Matt
M
Maestro
Roberta
R
de Alava
Enrique
E
Madoz-Gúrpide
Juan
J
Pilotti
Silvana
S
von Mehren
Margaret
M
Pedeutour
Florence
F
Maki
Robert G
RG
Rutkowski
Piotr
P
Thomas
David M
DM
D002817:Chordoma / Q000188:drug therapy; D051358:Cyclin-Dependent Kinase 4 / Q000235:genetics; D055808:Drug Discovery; D006801:Humans; D008080:Liposarcoma / Q000188:drug therapy / Q000235:genetics; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D040901:Proteomics; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics; D012509:Sarcoma / Q000098:blood supply / Q000188:drug therapy* / Q000235:genetics
C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; C495900:CDK4 protein, human; D051358:Cyclin-Dependent Kinase 4